In a complex therapeutic landscape, WuXi AppTec is simplifying the path from discovery to patient. Find out how.

The custom antibody market is projected to grow at a CAGR of approximately 10% throughout the forecast period. This expansion is driven by increasing R&D activity, rising demand for highly specific ...

Linden Lake Labs ("L3"), an early-stage life sciences platform committed to advancing innovative therapies, today announced that its portfolio company, CrossBridge Bio, has entered into a definitive ...

Pharmaceutical companies already use artificial intelligence for tasks like optimizing clinical trials, identifying drug targets and developing predictive models for risk detection. But AI’s next ...

OncoNano Medicine, Inc. ("OncoNano"), a clinical-stage biotechnology company developing precision therapies using its proprietary nanotechnology platform, today announced it will present new ...

Chemokines, acting as "traffic controllers" in the tumor microenvironment, regulate immune cell infiltration and local ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

Zai Lab Limited today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and robust intracranial ...

The world's most powerful supercomputer isn't just incredibly capable, it's also the largest one in the U.S. — at least, if ...

Researchers at the Université de Genève have built a DNA-based drug delivery system that reads pairs of protein markers on a cell’s surface, decides whether the cell is cancerous, and then floods it ...

University of Birmingham researchers are testing new therapies for rare childhood lymphoma through a unique global platform study.

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can precisely ...